HeartFlow Analysis vs FFRct

Direct competitors — feature-level head-to-head below. Comparability 95/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

HeartFlow Analysis

by HeartFlow

FFRct

by HeartFlow

AI Verdict

Both "HeartFlow Analysis" and "FFRct" are offerings from HeartFlow, providing non-invasive, AI-powered diagnostic solutions for coronary artery disease by creating personalized 3D models from CT/CCTA scans and assessing blood flow. While "FFRct" specifically highlights the Fractional Flow Reserve derived from CT analysis, "HeartFlow Analysis" appears to be the broader product suite, encompassing FFRct analysis along with additional features like Plaque Analysis and Roadmap™ Analysis. Therefore, they are highly comparable as they address the same clinical need with the same underlying technology from the same vendor.

Choose HeartFlow Analysis if…

Choose HeartFlow Analysis if your clinical workflow requires a comprehensive assessment of coronary artery disease that includes not only functional blood flow analysis (FFRct) but also detailed quantification and characterization of plaque. This tool is ideal for clinicians seeking deeper insights into plaque burden and morphology in addition to hemodynamic significance, leveraging its AI-enabled quantitative plaque analysis capabilities.

View HeartFlow Analysis →

Choose FFRct if…

Choose HeartFlow FFRct Analysis if your primary objective is to non-invasively assess the functional significance of coronary artery stenoses by deriving FFRct values from CCTA scans. This tool is best suited for guiding revascularization decisions and determining the need for invasive procedures based on accurate blood flow analysis.

View FFRct →

Both HeartFlow Analysis and HeartFlow FFRct are AI-powered, cloud-based tools from HeartFlow designed to non-invasively diagnose and manage coronary artery disease (CAD) using personalized 3D models derived from CT scans. They share core functionalities, including the use of computational fluid dynamics (CFD) to assess blood flow and aid in identifying areas of narrowing in coronary arteries. Both tools are FDA-cleared, HIPAA-compliant, and covered by Medicare and most U.S. commercial payers, with established CMS payment rates for FFRct Analysis.

The key practical difference lies in their scope. HeartFlow Analysis offers a broader suite of features, including AI-Enabled Quantitative Plaque Analysis (CPT code 75577 for 2026) and Roadmap™ Analysis for CCTA reading, in addition to the Fractional Flow Reserve derived from CT (FFRct) analysis. HeartFlow FFRct, while robust in its FFRct capabilities, focuses specifically on this aspect. Therefore, a physician primarily interested in a comprehensive assessment that includes plaque quantification and characterization alongside FFRct values may find HeartFlow Analysis more suitable. Conversely, a physician whose diagnostic workflow primarily requires FFRct analysis for blood flow assessment might find HeartFlow FFRct to be a more streamlined option.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	HeartFlow Analysis	FFRct
Pricing	Contact vendor for pricing	Contact for pricing
Deployment	Cloud-based (AWS)	Cloud-based (HeartFlow Network, AWS Cloud or Virtual Private Cloud), with a local Virtual Appliance for data transfer.
BAA Available	Yes AI-estimated	Unknown
FDA Status	Yes AI-estimated	1 AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

HeartFlow Analysis

HeartFlow Analysis (Tool A) includes Plaque Analysis and Roadmapu2122 Analysis, with recent updates highlighting an 'interactive experience' for plaque analysis, suggesting a richer and potentially more interactive user interface for clinicians. While the core process of sending CCTA data and receiving a report is similar for both, implying ease of use for the clinician in terms of workflow integration, Tool A's broader feature set offers more comprehensive interaction.

Clinical Value

HeartFlow Analysis

HeartFlow Analysis (Tool A) offers superior clinical value by integrating both FFRct analysis and Plaque Analysis, which provides a more comprehensive assessment of coronary artery disease, including quantification and characterization of plaque. This combined approach has been shown to enhance clinical decision-making, improve patient outcomes, and refine risk assessment beyond FFRct alone, with Plaque Analysis being supported by ACC/AHA scientific statements.

Pricing & Value

HeartFlow Analysis

While both tools require direct vendor contact for pricing and demonstrate cost-effectiveness by reducing downstream invasive procedures, HeartFlow Analysis (Tool A) offers a stronger overall value proposition. It includes both FFRct and AI-Enabled Quantitative Plaque Analysis, both of which have established Category I CPT codes and CMS payment rates, providing more comprehensive diagnostic insights for a potentially similar or incrementally higher, yet reimbursable, cost.

Enterprise Readiness

FFRct

Both tools demonstrate strong enterprise readiness with FDA clearance, HIPAA compliance, and BAA availability, and both are cloud-based. However, Tool B's explicit mention of flexible deployment options, including 'AWS Cloud or Virtual Private Cloud, with a local Virtual Appliance for data transfer,' suggests a slightly more adaptable solution for diverse enterprise IT infrastructures and data management preferences compared to Tool A's more general 'Cloud-based (AWS)' description.

Innovation

HeartFlow Analysis

While both tools are fundamentally innovative in their use of AI and computational fluid dynamics for non-invasive FFRct analysis, HeartFlow Analysis (Tool A) demonstrates a broader scope of innovation. Its explicit inclusion of 'Plaque Analysis (quantification and characterization)' and 'Roadmapu2122 Analysis' represents additional innovative advancements that provide deeper insights into coronary artery disease beyond just blood flow assessment, particularly with recent updates to an 'interactive experience' for plaque analysis.

Support & Docs

Tie

The provided structured facts do not contain specific information regarding support and documentation for either tool. Given that both are products from the same company, HeartFlow, it is reasonable to assume they leverage a common support infrastructure and documentation resources, making it impossible to distinguish between them on this dimension without further specific details.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	HeartFlow Analysis	FFRct
Product Name	HeartFlow Analysis	FFRct
Company	HeartFlow	HeartFlow
Tagline	Decisive Coronary Care	Redefining what's possible in coronary care.
Primary Use Case	Non-invasive solution for diagnosing and managing coronary artery disease (CAD) by creating personalized 3D models of patients' coronary arteries from standard CT scans.	Non-invasive AI-powered diagnostic tool that creates personalized 3D models of coronary arteries from CCTA scans to assess blood flow and aid in diagnosing coronary artery disease.
CMS Payment/Coverage	Covered by Medicare and most U.S. commercial payers; CMS payment rates for FFRct Analysis and Plaque Analysis are established.	CMS payment rate for FFRct Analysis: $1,017 (2025); Commercial payer rates vary.
CPT Codes	Category I CPT code for FFRct Analysis (75580) and AI-Enabled Quantitative Plaque Analysis (75577 for 2026).	Not specified